Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Gynecol Oncol. 2016 Jun 30;142(3):539–547. doi: 10.1016/j.ygyno.2016.06.017

Figure 5. Inhibition of Wnt pathway may lead to cell dormancy and development to cisplatin resistance.

Figure 5

A-B.Proliferation assay measures the number of viable A2780 and SKOV3 cells treated with cisplatin (48hrs) at the indicated concentrations after 4 hour pretreatment with control or Wnt3A (150ng/ml). C-D. Proliferation assay measures the number of viable A2780 and SKOV3 cells treated with cisplatin (48hrs) at the indicated concentrations after 4 hour pretreatment with the inhibitor XAV-939 (250ng/ml). Bars represent means ± SE. * denotes statistical significance (p < 0.05) E. Proliferation assay measures the number of viable SKOV3 cells stably transduced with shTMEM88 vs shControl and treated with cisplatin at the indicated concentrations. F. Model illustrating the potential role of TMEM88 in the development of OC platinum resistance.